Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.
- Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.
- Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience.
- He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company.
- “We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company,” said Tentarix Chairman Donald Santel.